Market Overview

Midatech Pharma Rallies On Positive MTX102 Results

Midatech Pharma Rallies On Positive MTX102 Results

Midatech Pharma PLC-ADR (NASDAQ: MTP) shares were trading higher Friday after the company announced positive results from a first-in-human study of its MTX102 immuno-tolerizing vaccine product candidate in diabetes.

The results showed that MTX102 was well-tolerated, with asymptomatic local injection site reactions being the only drug-related finding, and no serious adverse events were reported, according to Midatech

“This EU-funded program is an invaluable project to further develop, understand and evaluate Midatech’s gold nanoparticle technology, MidaCore,” CEO Craig Cook said in a statement.

"This is the first human study to assess the safety of MidaCore when injected into patients, and we are pleased that the data generated to date validates the technology as a potentially innovative treatment platform for medical applications." 

Midatech shares were trading higher by 45.38% at $1.89 at the time of publication Friday. The stock has a 52-week high of $10.90 and a 52-week low of $1.03.

Related Links:

Eton Pharmaceuticals Shares Slammed After FDA Complete Response Letter

Neon Therapeutics Shares Higher After Positive Cancer Vaccine Study

Posted-In: Diabetes MTX102 VaccinesBiotech News Penny Stocks Markets General Best of Benzinga


Related Articles (MTP)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Mid-Afternoon Market Update: Skechers Surges On Upbeat Earnings; J C Penney Shares Slide

Benchmark Downgrades Autohome On Growth Outlook Concerns Amid Weakness In Auto Sales